Exogenus Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 8

Exogenus Therapeutics General Information

Description

Developer of an exosome-based platform technology designed to offer an innovative pipeline of therapeutic products. The company's platform leverages the strong regenerative, anti-inflammatory and immunomodulatory properties of proprietary vesicles, enabling healthcare providers to access a pipeline of products for skin and autoimmune diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Corporate Office
  • Biocant Park Núcleo 04
  • Lote 2
  • Cantanhede, 3060-197
  • Portugal
+351 231 000 000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Exogenus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 24-Apr-2024 00000 Completed Generating Revenue
6. Accelerator/Incubator 08-Nov-2022 00000 Completed Generating Revenue
5. Grant 17-Oct-2016 000.00 00000 Completed Generating Revenue
4. Early Stage VC 10-Dec-2015 00000 00000 00.000 Completed Generating Revenue
3. Grant 000.00 00000 Completed Generating Revenue
2. Accelerator/Incubator 01-Jan-2015 $123K $123K Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Exogenus Therapeutics’s complete valuation and funding history, request access »

Exogenus Therapeutics Patents

Exogenus Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210369789-A1 Compositions comprising small extracellular vesicles derived from umbilical cord blood mononuclear cells with anti-inflammatory and immunomodulatory properties and process for obtaining them Pending 04-Oct-2018 000000000 0
EP-3860626-A2 Compositions comprising small extracellular vesicles derived from umbilical cord blood mononuclear cells with anti-inflammatory and immunomodulatory properties and process for obtaining them Pending 04-Oct-2018 000000000

Exogenus Therapeutics Executive Team (6)

Name Title Board Seat
Joana Correia Ph.D Co-Founder, Chief Executive Officer, Chief Scientific Officer & Executive Director
Luisa Marques Co-Founder & Chief Operating Officer
David Magboulé Advisor
Kostas Alevizopoulos Ph.D Strategic Advisor
You’re viewing 4 of 6 executive team members. Get the full list »

Exogenus Therapeutics Board Members (2)

Name Representing Role Since
Pedro Vilarinho Ph.D Acelerador de Comercialização de Tecnologias Board Member 000 0000
Walter Palma Self Board Member 000 0000
To view Exogenus Therapeutics’s complete board members history, request access »

Exogenus Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Exogenus Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
3xP Global Asset Manager Minority 000 0000 000000 0
Blue Bio Value Accelerator/Incubator 000 0000 000000 0
Horizon 2020 SME Instrument Government 000 0000 000000 0
Change Partners Venture Capital Minority 000 0000 000000 0
Finova PE-Backed Company Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Exogenus Therapeutics FAQs

  • When was Exogenus Therapeutics founded?

    Exogenus Therapeutics was founded in 2015.

  • Who is the founder of Exogenus Therapeutics?

    Joana Correia Ph.D, Luisa Marques, and Ricardo Neves Ph.D are the founders of Exogenus Therapeutics.

  • Who is the CEO of Exogenus Therapeutics?

    Joana Correia Ph.D is the CEO of Exogenus Therapeutics.

  • Where is Exogenus Therapeutics headquartered?

    Exogenus Therapeutics is headquartered in Cantanhede, Portugal.

  • What is the size of Exogenus Therapeutics?

    Exogenus Therapeutics has 10 total employees.

  • What industry is Exogenus Therapeutics in?

    Exogenus Therapeutics’s primary industry is Biotechnology.

  • Is Exogenus Therapeutics a private or public company?

    Exogenus Therapeutics is a Private company.

  • What is Exogenus Therapeutics’s current revenue?

    The current revenue for Exogenus Therapeutics is 000000.

  • How much funding has Exogenus Therapeutics raised over time?

    Exogenus Therapeutics has raised $981K.

  • Who are Exogenus Therapeutics’s investors?

    3xP Global, Blue Bio Value, Horizon 2020 SME Instrument, Change Partners, and Finova are 5 of 8 investors who have invested in Exogenus Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »